This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

OX-MPI

Boehringer Ingelheim GmbH

Drug Names(s): OX-MPI

Description: OX-MPI is derived from an entirely new mechanism based on the identification of a specific enzyme – membrane-bound prostaglandin (PG) E synthase (mPGES). This enzyme is necessary for the production of PGE2, a substance produced by the body which plays a pivotal role in many inflammatory processes.

Deal Structure: Orexo and Boehringer Ingelheim
In November 2005, an exclusive collaboration and license agreement for the development and commercialization of OX-MPI was signed with Boehringer Ingelheim.

Partners: Orexo AB


OX-MPI News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug